Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
2019 · Journal for ImmunoTherapy of Cancer · 205 citations
https://doi.org/10.1186/s40425-019-0634-9
M
Marion Thibaudin
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
86
Papers
2.1K
Citations
17
h-index
19
i10-index
Marion Thibaudin is an academic researcher from Inserm. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Colorectal Cancer Treatments and Studies & Immune Cell Function and Interaction. The author has an h-index of 17, co-authored 74 publications.
ORCID: 0000-0002-1046-5982Papers by this author
worksMEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
2022 · Cancer Cell · 199 citations
https://doi.org/10.1016/j.ccell.2021.12.009
Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation
2017 · Cell Reports · 130 citations
https://doi.org/10.1016/j.celrep.2017.04.004
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
2023 · Nature Medicine · 96 citations
https://doi.org/10.1038/s41591-023-02497-z
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
2020 · BMC Cancer · 48 citations
https://doi.org/10.1186/s12885-020-07253-x
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial
2025 · Signal Transduction and Targeted Therapy · 2 citations
https://doi.org/10.1038/s41392-024-02116-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat